All Companies articles – Page 6
-
ArticleNasal drug delivery: the non-invasive future of treatment
Advances in formulation science and device technology are transforming nasal drug delivery, enhancing absorption, stability and patient adherence. This article examines the innovations driving its growth and highlights future applications ranging from systemic treatments to nose-to-brain therapies and vaccines.
-
NewsScientists use AI to create antibodies entirely from scratch
Scientists at the University of Washington’s Institute for Protein Design have used artificial intelligence to create antibodies entirely from scratch, a breakthrough that could reshape drug discovery.
-
ArticleBeyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
-
NewsZuckerberg's Biohub announces AI-powered biology to accelerate drug discovery
The initiative combines cutting-edge artificial intelligence with large-scale biological data, with the aim to transform how new treatments, drugs and therapies are developed.
-
ArticleRecombinant KLK1: the next step in stroke and preeclampsia treatment
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to restore blood flow, improve endothelial function and address unmet needs in the treatment of stroke and preeclampsia.
-
ArticleInside ELRIG Drug Discovery 2025: automation, AI and human-relevant models
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
-
ArticleIL-2 and GLP-1 receptor agonist combination tackles neuroinflammation
Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.
-
NewsNuclera expands into Australasia with Solve Scientific partnership
Cambridge-based biotech firm Nuclera has partnered with Solve Scientific Australia to expand access to its eProtein Discovery™ System across Australia and New Zealand.
-
ReportLab Automation: Where Discovery Scales
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
-
ArticleCD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
-
ArticleWhen chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
-
NewsSwallowable bioluminescent pill detects early signs of gut ischaemia
Scientists have developed an ingestible, light-emitting capsule that can detect life-threatening intestinal blood flow problems in their earliest stages. The device could offer doctors a faster and less invasive way to diagnose acute mesenteric ischaemia.
-
NewsNew PET tracer could lead to better ALS and Alzheimer’s diagnosis
New preclinical data on ACI-19626, a first-in-class PET tracer for imaging TDP-43 pathology, shows potential to greatly improve early diagnosis and treatment of multiple neurodegenerative diseases.
-
ArticleFrom wild fungi to faster drug discovery
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
-
ArticleFrom war rooms to launch rooms: how AI is changing the game
Within3’s Jason Smith explores how artificial intelligence is breathing new life into next-generation launch situation rooms; delivering actionable insights for pharmaceutical companies.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part II
Part II shows that the predictive validity crisis can be solved by rethinking how the industry chooses models, measures outcomes and integrates systems. Success stories from Vertex, Regeneron and AstraZeneca illustrate how aligning biology, measurement and strategy can reverse decades of declining productivity.
-
ArticleHow real-world data is accelerating drug discovery
Vish Srivastava considers the benefits of expanding the role of real-world data in drug discovery to provide improved therapies, faster and with greater success.
-
ArticleBuilding reliable organoid models for human-relevant drug discovery
Organoids are changing the landscape of biomedical research, with automation and AI driving new levels of consistency, scalability and human relevance. Aaron Risinger of Molecular Devices discusses how these technologies are advancing precision medicine – and the challenges that remain.
-
NewsMeta-Flux expands AI platform to speed up drug development
Dublin-based biotech Meta-Flux has raised €1.8M ($2M) in seed funding to expand its AI-driven platform for preclinical drug development, helping researchers predict drug success and accelerate the pathway from lab to clinic.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part I
Drug discovery now costs 100 times more per FDA-approved drug than in 1950, despite vast advances in biology and computing. The core problem is the collapse of predictive validity in preclinical models, which sits at the heart of pharma’s productivity paradox.